{"id":207,"date":"2024-06-14T13:38:00","date_gmt":"2024-06-14T13:38:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=207"},"modified":"2025-09-05T13:52:47","modified_gmt":"2025-09-05T13:52:47","slug":"china-bd-2024-futuregen-and-abbvie-enters-a-1-71-billion-usd-license-on-tl1a-antibody-fg-m701","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2024\/207.html","title":{"rendered":"[China BD 2024] FutureGen and AbbVie enters a 1.71 billion USD license on TL1A antibody FG-M701"},"content":{"rendered":"\n<p>Announced Date: 2024-06-13 (&nbsp;June 13, 2024)<\/p>\n\n\n\n<p>Asset Name: FG-M701<\/p>\n\n\n\n<p>Licensor: FutureGen Biopharmaceutical (Beijing)&nbsp;(China)<\/p>\n\n\n\n<p>Licensee (Buyer): AbbVie Inc.\uff08US\uff09<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: fully human monoclonal antibody<\/p>\n\n\n\n<p>Asset Target: TL1A<\/p>\n\n\n\n<p>Potential Indication: treatment of inflammatory bowel disease (IBD)<\/p>\n\n\n\n<p>Current Stage:  Preclinical<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority: <\/p>\n\n\n\n<p>AbbVie will receive an exclusive global license to develop, manufacture and commercialize FG-M701.&nbsp;<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>FutureGen will receive<\/p>\n\n\n\n<p>$150 million&nbsp;in upfront and near-term milestone payments,<\/p>\n\n\n\n<p>up to an additional&nbsp;$1.56 billion&nbsp;in clinical development, regulatory and commercial milestones, <\/p>\n\n\n\n<p>tiered royalties up to low-double digits on net sales.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/news.abbvie.com\/2024-06-13-AbbVie-and-FutureGen-Announce-License-Agreement-to-Develop-Next-Generation-Therapy-for-Inflammatory-Bowel-Disease\">AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease &#8211; Jun 13, 2024<\/a><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Note: <\/p>\n\n\n\n<p>Chinese Name of FutureGen Biopharmaceutical (Beijing)\u00a0 \u660e\u6d4e\u751f\u7269\u5236\u836f\uff08\u5317\u4eac\uff09<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2024-06-13 (&nbsp;June 13, 2024) Asset Name: FG-M701 Licensor: FutureGen Biopharmaceutical (Beijing)&nbsp;(China) Licensee (Buyer): AbbVie &hellip; <a title=\"[China BD 2024] FutureGen and AbbVie enters a 1.71 billion USD license on TL1A antibody FG-M701\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2024\/207.html\"><span class=\"screen-reader-text\">[China BD 2024] FutureGen and AbbVie enters a 1.71 billion USD license on TL1A antibody FG-M701<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-207","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=207"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/207\/revisions"}],"predecessor-version":[{"id":210,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/207\/revisions\/210"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}